Trastuzumab-Associated Dermatomyositis

Waheed, Saadia; Zubair, Hafiz Muhammad; Waheed, Farishta; Iqbal, Shumaila Muhammad

doi:10.1097/mjt.0000000000000849

Cited by 4 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, trastuzumab-related myotoxicity has been associated with dermatomyositis. 10,11 Our patient reported onset of muscle weakness after the patient's treatment regimen was switched from pertuzumab to gemcitabine. Furthermore, the patient did not have any skin symptoms, largely excluding trastuzumab as the causative agent.…”

Section: Discussionmentioning

confidence: 93%

Gemcitabine-Induced Myositis in a Luminal B Breast Cancer patient: A Case Report

Badran

Ali

Arabi

et al. 2023

Clin Med Insights Case Rep

View full text Add to dashboard Cite

Human epidermal growth factor receptor-positive breast cancer is an aggressive cancer which represents approximately a quarter of all breast cancers worldwide. Recent advances have led to the development of targeted therapies, such as trastuzumab (H), which have significantly improved prognosis. Such therapies are currently used alongside other chemotherapeutic agents, such as paclitaxel (P) and gemcitabine (G). The most common side effects of PGH combination therapy include thrombocytopenia and anemias. However, there have been no previous reports of myositis resulting from this combination. We report the case of a 54-year-old metastatic breast cancer patient on PGH therapy who developed muscle weakness. The patient was initially treated with trastuzumab, pertuzumab, and paclitaxel. However, pertuzumab was changed to gemcitabine due to severe diarrhea. After the fourth cycle of PGH, the patient presented with muscle weakness and creatine kinase levels of up to 6755 U/L. Magnetic resonance imaging of the femur and pelvis revealed diffuse bilateral myositis, suggesting a diagnosis of gemcitabine-induced myositis. The patient was placed on intravenous fluids and corticosteroids, which resolved her condition. To our knowledge, this is the first report of gemcitabine-induced myositis in a breast cancer patient. Further studies are needed to determine the underlying mechanisms of gemcitabine-induced myositis and develop preventative measures.

show abstract

Section: Discussionmentioning

confidence: 93%

Gemcitabine-Induced Myositis in a Luminal B Breast Cancer patient: A Case Report

Badran

Ali

Arabi

et al. 2023

Clin Med Insights Case Rep

View full text Add to dashboard Cite

show abstract

“…Subsequently, phototoxic reactions to treatment with trastuzumab and taxanes were reported and included vacuolar changes along the dermal–epidermal junction and perivascular lymphohistiocytic infiltrates in the upper dermis 58,66 . A few authors reported dermatomyositis with trastuzumab use, 40–42 probably because of its mediation of antibody‐dependent cell‐mediated cytotoxicity by binding to Fcγ receptors and regulation of the immune response 238 …”

Section: Resultsmentioning

confidence: 99%

The diverse landscape of dermatologic toxicities of non‐immune checkpoint inhibitor monoclonal antibody‐based cancer therapy

et al. 2022

View full text Add to dashboard Cite

Background Since their first approval 25 years ago, monoclonal antibodies (mAbs) have become important targeted cancer therapeutics. However, dermatologic toxicities associated with non−immune checkpoint inhibitor (non‐ICI) mAbs may complicate the course of cancer treatment. Data on the incidence and types of these reactions are limited. Methods A comprehensive review was conducted on dermatologic toxicities associated with different classes of non‐ICI mAbs approved for treatment of solid tumors and hematologic malignancies. The review included prospective Phase 1, 2, and 3 clinical trials; retrospective literature reviews; systematic reviews/meta‐analyses; and case series/reports. Results Dermatologic toxicities were associated with several types of non‐ICI mAbs. Inflammatory reactions were the most common dermatologic toxicities, manifesting as maculopapular, urticarial, papulopustular/acneiform, and lichenoid/interface cutaneous adverse events (cAEs) with non‐ICI mAbs. Immunobullous reactions were rare and a subset of non‐ICI mAbs were associated with the development of vitiligo cAEs. Conclusion Dermatologic toxicities of non‐ICI mAbs are diverse and mostly limited to inflammatory reactions. Awareness of the spectrum of the histopathologic patterns of cAE from non‐ICI mAbs therapy is critical in the era of oncodermatology and oncodermatopathology.

show abstract

“…Another uncommon adverse event is carotenoderma, also referred to as carotenosis cutis, and aurantiasis cutis refers to the manifestation of yelloworange skin coloration resulting from carotenemia (41). There have also been reported cases of trastuzumab induced dermatomyositis, a complement-mediated idiopathic inflammatory myopathy manifested by skin changes and proximal muscle weakness (42).…”

Section: Trastuzumabmentioning

confidence: 99%

Dermatologic Toxicities of Targeted Therapy and Immunotherapy in Head and Neck Cancers

et al. 2021

View full text Add to dashboard Cite

Treatment of head and neck cancers requires multidisciplinary collaboration to reduce morbidity and mortality associated with the tumor burden, as well as to preserve function of organs and structures. With the use of various new targeted therapies come new adverse events including dermatologic toxicities, which may consist of xerosis, nail and hair changes, morbilliform or papulopustular rashes, to more severe eruptions such as Stevens–Johnson syndrome. We describe the dermatologic toxicities and corresponding grades of severity and associated pathophysiology resulting from seven therapeutics used to treat head and neck cancers: cetuximab, trastuzumab, pembrolizumab, nivolumab, lentatinib, larotrectinib, and entrectinib. Being familiar with these dermatologic toxicities allows clinicians to provide comprehensive counseling for patients, encourage preventative measures, and to know when it is appropriate to hold therapy or permanently stop treatment.

show abstract

Trastuzumab-Associated Dermatomyositis

Cited by 4 publications

References 5 publications

Gemcitabine-Induced Myositis in a Luminal B Breast Cancer patient: A Case Report

Gemcitabine-Induced Myositis in a Luminal B Breast Cancer patient: A Case Report

The diverse landscape of dermatologic toxicities of non‐immune checkpoint inhibitor monoclonal antibody‐based cancer therapy

Dermatologic Toxicities of Targeted Therapy and Immunotherapy in Head and Neck Cancers

Contact Info

Product

Resources

About